SGMO Sangamo Therapeutics Inc.

$25.35 +14.19%

13,412,188 Shares Traded
1,743,164 Average Volume (last 30 days)

as of February 22, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Lost on the Day: $25.49 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-26.5%
If Intiated One Month Ago, Shorts Have Realized a Return of:-14.43%
If Initiated Five Days ago, Shorts Have Realized a Return of:1.55%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingShort Squeeze Either Occurring or Squeeze Potential Rising - Pay More Attention to Catalysts and Fundamentals
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 9.79%
Short Interest8.09 million
Float82.64 million
Short Ratio5.45
Market Cap$1.88 billion
Market Maker ActivityDaily Short Volume

News

02-22-2018
Sangamo bulls running after Gilead deal; shares up 13.4% (SeekingAlpha)
02-22-2018
Midday Gainers / Losers (2/22/2018) (SeekingAlpha)
02-22-2018
Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement (SeekingAlpha)
02-22-2018
Premarket Gainers as of 9:05 am (02/22/2018) (SeekingAlpha)
02-22-2018
Sangamo Therapeutics Q4 revenues up 47%; shares ahead 7% premarket (SeekingAlpha)
02-22-2018
Sangamo up 6% premarket on Gilead deal to develop oncology-focused cell therapies (SeekingAlpha)
02-22-2018
Sangamo Therapeutics beats by $0.03, beats on revenue (SeekingAlpha)
02-22-2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer (PR Newswire)
02-22-2018
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer (Business Wire)
02-22-2018
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results (PR Newswire)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 62.2%

Earnings Stats

PE Ratio -36.81
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $13.01
50 Day Moving Average $18.66
52 Week High $23.9
52 Week Low $3.65



Data provided for free by IEX. Questions? Read the FAQ